Sucralfate Intestinal Barrier Composition for Nutrient Absorption Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus (T2DM), such as medications and surgeries like RYGB, have limitations including side effects, poor compliance, and are not suitable for all patients, while less invasive options like duodeno-jejunal bypass sleeve pose risks and require frequent device removal.
Innovation Solution
Compositions comprising aluminum cross-linked sulfated agents, such as sucralfate, combined with a particle stabilizer and humectant, form a barrier on the intestinal lining to modulate nutrient absorption, reducing the absorption of nutrients like glucose, thereby treating conditions like T2DM and obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RYGB surgery is performed to treat T2DM, then metabolic improvement and weight loss are achieved, but surgical risks and invasiveness increase
Solution Approach 1:
The patent replaces the mechanical surgical intervention (RYGB surgery) with a chemical/pharmacological approach using sucralfate composition that forms a gel barrier in the duodenum. This substitution eliminates surgical risks while achieving similar metabolic effects through inhibition of nutrient absorption in the duodenum, the key site for glucose absorption.
Solution Approach 2:
The sucralfate-based gel composition acts as an intermediary substance that mediates between the food intake and the duodenal mucosa. It forms a protective barrier that prevents direct contact between nutrients and the absorption surface, thereby reducing glucose absorption without requiring surgical alteration of the gastrointestinal tract.
2Reliability
If duodeno-jejunal bypass sleeve is implanted to prevent nutrient contact, then T2DM treatment efficacy is improved, but device complexity and procedural risks increase
Solution Approach 1:
The patent employs a disposable oral formulation (sucralfate composition) that temporarily forms a gel barrier for a sufficient duration to achieve therapeutic effect, then is naturally excreted. This eliminates the need for permanent implanted devices, reducing device complexity, implantation procedures, and associated risks while maintaining treatment efficacy.
Solution Approach 2:
The patent extracts the essential function of the bypass sleeve (preventing nutrient-mucosa contact in the duodenum) and achieves it through a simpler chemical means rather than a complex mechanical device. The sucralfate gel performs the same protective function without requiring endoscopic implantation or annual removal procedures.
3Reliability
If sucralfate is used to form intestinal barrier, then nutrient absorption is reduced, but aluminum release increases
Solution Approach 1:
The patent uses a composite formulation where sucralfate is combined with other components (such as hydrophilic polymers, surfactants, or binding agents) that modify its properties. This composite approach maintains the barrier-forming capability of sucralfate while reducing aluminum release through chemical modification or physical encapsulation within the gel matrix.
Solution Approach 2:
The patent modifies the physical and chemical parameters of sucralfate by adjusting pH, ionic strength, or molecular structure through formulation with additional compounds. These parameter changes reduce aluminum solubility and release while preserving the gel-forming and barrier properties necessary for effective nutrient absorption inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively reduce nutrient absorption, providing a safer and less invasive treatment option for T2DM and obesity by forming a stable barrier that minimizes aluminum release and maintains efficacy over time.
Implementation Method 1
modulate absorption of nutrients through the intestinal lining by forming a barrier on the intestine wall
Implementation Method 2
reducing the absorption of nutrients like glucose
Data Source
AI summary
This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.